Lundbeck Cuts 150 R&D Jobs To Control Costs Ahead Of Key Patent Expiry

Danish pharma increases investment in new product launches as it prepares for loss of patent protection on its lead product, escitalopram.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet